With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors [Yahoo! Finance]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Yahoo! Finance
A total of 5 investors have a majority stake in the company with 55% ownership Insiders have bought recently A look at the shareholders of Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 40% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's delve deeper into each type of owner of Entrada Therapeutics, beginning with the chart below. See our latest analysis for Entrada Therapeutics What Does The Institutional Ownership Tell Us About Entrada Therapeutics? Institutional investors commonly compare their own returns to the returns of a commonly followed i
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Entrada Therapeutics Announces $100 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Announces $100 Million Registered Direct OfferingGlobeNewswire
- Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular DystrophyGlobeNewswire
TRDA
Earnings
- 5/7/24 - Beat
TRDA
Sec Filings
- 6/26/24 - Form SC
- 6/26/24 - Form 4
- 6/24/24 - Form 8-K
- TRDA's page on the SEC website